Placenta accreta: adherent placenta due to <scp>A</scp>sherman syndrome

Engelbrechtsen, Line; Langhoff‐Roos, Jens; Kjer, Jens Jørgen; Istre, Olav

doi:10.1002/ccr3.194

Cited by 30 publications

(19 citation statements)

References 31 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, obstetric complications should be observed, including placentation issues, prematurity and postpartum hysterectomy following treatment for IUAs (47). For example, intrauterine adhesions may lead to placenta accreta and the risk of severe postpartum haemorrhage (48). However, to the best of our knowledge, whether aspirin may decrease the obstetric complications with IUAs following surgery has not yet been described in the literature and requires long-term follow-up observations.…”

Section: Discussionmentioning

confidence: 99%

Aspirin inhibits endometrial fibrosis by suppressing the�TGF‑β1‑Smad2/Smad3 pathway in intrauterine adhesions

Zhang

Deng

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

Intrauterine adhesions (IUAs) represent one of the most common diseases in women of reproductive age. Patients with moderate-to-severe IUA can experience a decrease in normal menstrual patterns, amenorrhea and even infertility. At present, the first-line treatment strategies for IUAs in the clinical practice are hysteroscopic transuterine resection of adhesion and postoperative adjuvant therapy, including oestrogen. However, a high recurrence rate of IUAs remains.

show abstract

Section: Discussionmentioning

confidence: 99%

Aspirin inhibits endometrial fibrosis by suppressing the�TGF‑β1‑Smad2/Smad3 pathway in intrauterine adhesions

Zhang

Deng

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…The current results agreed with researchers who found increases in TNF, IL-1β, and IL-6 in bronchoalveolar lavage fluid in pulmonary fibrosis rat model [ 23 ]. Estrogen can promote the growth of endometriotic lesions by increasing the TNF levels [ 24 ]. BMSCs treatment resulted in the regeneration of the endometrium via modulation of the expression of proinflammatory cytokines TNF and IL-1 in experimental rats [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats

et al. 2017

View full text Add to dashboard Cite

Endometrial fibrosis is the presence of intrauterine adhesions (IUAs) after any uterine surgery or curettage and it results in infertility and recurrent pregnancy loss. We evaluated the role of human mesenchymal stem cells (hMSCs) as a therapeutic agent of endometrial fibrosis. We also compared the effect of MSCs with the effect of estrogen and neupogen either each alone or as a combined therapy with MSCs. This experimental study was performed on 84 albino rats which were divided into seven groups (n=12 rats/group) as follows, group1: normal control rats, group 2: induced fibrosis, group 3: induced fibrosis that received oral estrogen, group 4: induced fibrosis that received hMSCs, group 5: induced fibrosis that received hMSCs and estrogen, group 6: induced fibrosis that received neupogen, and group 7: induced fibrosis that received hMSCs and neupogen. The extent of fibrosis, vascularization, and inflammation were evaluated by; qRT-PCR for interleukin 1 (IL-1), interleukin 6 (IL-6), TNF, vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and RUNX; ELISA for connective tissue growth factor (CTGF); Western blotting for collagen-I; immunohistochemistry examination for VEGF and RUNX-2; and histopathological assessment. In therapeutic groups either by hMSCs alone or combined with estrogen or neupogen; fibrosis and inflammation (IL-1, IL-6, TNF, TGF-β, RUNX, CTGF, and collagen-I) were significantly decreased but vascularization (VEGF) was significantly increased (P<0.05) compared with induced fibrosis group. The most significant result was obtained in fibrosis that received combined therapy of hMSCs and neupogen (P=0.000). Stem cells and neupogen are a highly effective alternative regenerative agents in endometrial fibrosis.

show abstract

“…A recent case study has reported an abnormally invasive placenta as a result of uterine scarring in a patient with Asherman's syndrome. 18 Therefore, awareness of the possible development of MAP is important in pregnant women with a history of intrauterine procedure without caesarean section scar or placenta praevia.…”

Section: Discussionmentioning

confidence: 99%

Rising incidence of morbidly adherent placenta and its association with previous caesarean section: a 15-year analysis in a tertiary hospital in Hong Kong

Cheng

Lee

2015

Hong Kong Med J

View full text Add to dashboard Cite

show abstract

Placenta accreta: adherent placenta due to Asherman syndrome

Abstract: Key Clinical MessageIt is important to be aware of the risk of abnormally invasive placenta in patients with a history of Asherman syndrome and uterine scarring. A prenatal diagnosis by ultrasonography is useful when planning of mode of delivery.

Cited by 30 publications

References 31 publications

Aspirin inhibits endometrial fibrosis by suppressing the�TGF‑β1‑Smad2/Smad3 pathway in intrauterine adhesions

Aspirin inhibits endometrial fibrosis by suppressing the�TGF‑β1‑Smad2/Smad3 pathway in intrauterine adhesions

Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats

Rising incidence of morbidly adherent placenta and its association with previous caesarean section: a 15-year analysis in a tertiary hospital in Hong Kong

Contact Info

Product

Resources

About